Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-12-13 00:00:00 ET · period of report 2024-12-12 · accession 0001415889-24-029377 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-13 | 2024-12-12+ | SPRY | Chakma Justin | Chief Business Off | S - Sale+OE | $12.23 | -144.6K | 136.4K | -51% | -$1.77M |
| DM | 2024-12-13 | 2024-12-12+ | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.9532 | +144.6K | 253.7K | +133% | +$137.8K |
| DM | 2024-12-13 | 2024-12-12+ | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.00 | -144.6K | 55.5K | -72% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | S | D | 27,272 | $12.06 | 136,380 | D | — | — | (F2) The weighted average sale price for the transaction reported was $12.0625, and the range of prices were between $11.83 and $12.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2024-12-13 | M | A | 27,272 | $1.44 | 163,652 | D | — | — | |
| 3 | Common | Common Stock | 2024-12-12 | M | A | 117,333 | $0.84 | 253,713 | D | — | — | |
| 4 | Common | Common Stock | 2024-12-12 | S | D | 117,333 | $12.27 | 136,380 | D | — | — | (F1) The weighted average sale price for the transaction reported was $12.2653, and the range of prices were between $11.83 and $12.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-12-12 | M | D | 117,333 | $0.00 | 119,047 | D | $0.84 · — to 2029-07-04 | 117,333 Common Stock | (F3) Immediately exercisable. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-12-13 | M | D | 27,272 | $0.00 | 55,461 | D | $1.44 · — to 2031-12-13 | 27,272 Common Stock | (F3) Immediately exercisable. |